• 1
    Biggs R, Bidwell E. A method for the study of antihaemophilic globulin inhibitors with reference to six cases. Br J Haematol 1959; 5: 37995.
  • 2
    Nuss R, Jacobson L, Hathaway WE, Manco-Johnson M, Recombinate PUP Study Group. Evidence for antiphospholipid antibodies in children with factor VIII inhibitors. Thromb Haemost 1999; 82: 155960.
  • 3
    Blanco AN, Peirano AA, Grosso SH, Gennari LC, Perez Blanco R, Lazzari MA. A chromogenic substrate method for detecting and titrating anti-factor VIII antibodies in the presence of lupus anticoagulants. Haematologica 2002; 87: 2718.
  • 4
    Shaw PH, Reynolds S, Gunawardena S, Krishnamurti L, Ritchey AK. The prevalence of bleeding disorders among healthy pediatric patients with abnormal preprocedural coagulation studies. J Pediatr Hematol Oncol 2008; 30: 13541.
  • 5
    Manco-Johnson MJ, Nuss R, Jacobson LJ. Heparin neutralization is essential for accurate measurement of factor VIII activity and inhibitor assays in blood samples drawn from implanted venous access devices. J Lab Clin Med 2000; 136: 749.
  • 6
    Blanco AN, Peirano AA, Grosso SH, Gennari LC, Perez Blanco R, Lazzari MA. An ELISA system to detect anti-factor VIII antibodies without interference by lupus anticoagulants. Haematologica 2000; 85: 104550.
  • 7
    Lavigne-Lissalde G, Tarrade C, Lapalud P, Chtourou S, Schved JF, Granier C, Villard-Saussine S. Simultaneous detection and epitope mapping of anti-factor VIII antibodies. Thromb Haemost 2008; 99: 10906.
  • 8
    Krudysz-Amblo J, Parhami-Seren B, Butenas S, Brummel-Ziedins KE, Gomperts ED, Rivard GE, Mann KG. Quantitation of anti-factor VIII antibodies in human plasma. Blood 2009; 113: 258794.
  • 9
    Klinge J, Auerswald G, Budde U, Klose H, Kreuz W, Lenk H, Scandella D, The Paediatric Inhibitor Study Group of the German Society on Thrombosis and Haemostasis. Detection of all anti-factor VIII antibodies in haemophilia by the Bethesda assay and a more sensitive immunoprecipitation assay. Haemophilia 2001; 7: 2632.
  • 10
    Gilles JGG, Arnout J, Vermylen J, Saint-Remy J-MR. Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood 1993; 82: 245261.
  • 11
    Batlle J, Gomez E, Rendal E, Torea J, Loures E, Couselo M, Vila P, Sedano C, Tusell X, Magallon M, Quintana M, Gonzalez-Boullosa R, Lopez-Fernandez MF. Antibodies to factor VIIII in plasma of patients with hemophilia A and normal subjects. Ann Hematol 1996; 72: 3216.
  • 12
    Dazzi F, Tison T, Vianello F, Radossi P, Zerbinati P, Carraro P, Poletti A, Girolami A. High incidence of anti-FVIII antibodies against non-coagulant epitopes in haemophilia A patients: a possible role for the half-life of transfused FVIII. Br J Haematol 1996; 93: 68893.
  • 13
    Zakarija A, Harris S, Rademaker AW, Brewer J, Krudysz-Amblo J, Buenas S, Mann KG, Green D. Alloantibodies to factor VIII in haemophilia. Haemophilia 2011; 17: 63640.
  • 14
    Mondorf W, Klinge W, Luban NLC, Bray G, Saenko E, Scandella D, The Recombinate PUP Study Group. Low factor VIII recovery in haemophilia A patients without inhibitor titre is not due to the presence of anti-factor VIII antibodies undetectable by the Bethesda assay. Haemophilia 2001; 7: 139.
  • 15
    Kempton CL, Meeks SL, Donald Harvey R, Abshire TC. Evaluation of factor VIII pharmacokinetics and anti-factor VIII antibodies in four boys with haemophilia A and a poor clinical response to factor VIII. Haemophilia 2011; 17: 1556.
  • 16
    Caram C, de Souza RG, de Sousa JC, Pereira TA, Cerqueira AM, van der Bom JG, Rezende SM. The long-term course of factor VIII inhibitors in patients with congenital haemophilia A without immune tolerance induction. Thromb Haemost 2011; 105: 5965.
  • 17
    Soucie JM, Miller CH, Kelly FM, Payne AB, Creary M, Bockenstedt PL, Kempton CL, Manco-Johnson MJ, Neff AT, the Hemophilia Inhibitor Research Study Investigators. A pilot study of prospective surveillance for inhibitors among persons with hemophilia in the United States. Haemophilia 2013; in press.
  • 18
    Verbruggen B, Novakova I, Wessels H, Boezeman, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII: c inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 24751.
  • 19
    Miller CH, Platt SJ, Rice AS, Kelly F, Soucie JM, the Hemophilia Inhibitor Research Study Investigators. Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance. J Thromb Haemost 2012; 10: 105561.
  • 20
    de Maistre E, Wahl D, Perrett-Guillaume C, Regnault V, Clarac S, Briquel ME, Andre E, Lecompte T. A chromogenic assay allows reliable measurement of factor VIII levels in the presence of strong lupus anticoagulants. Thromb Haemost 1998; 79: 2378.
  • 21
    Chandler WL, Ferrell C, Lee J, Tun T, Kha H. Comparison of three methods for measuring factor VIII levels in plasma. Am J Clin Pathol 2003; 120: 349.
  • 22
    Hutton RA, Kamiguti Yamaga A, Matthews KB, Woodhams BJ. The use of a chromogenic assay for factor VIII in patients with factor VIII inhibitors or von Willebrand's disease. Thromb Res 1991; 63: 18993.
  • 23
    Hubbard AR, Bevan SA, Weller LJ. Potency estimation of recombinant factor VIII: effect of assay method and standard. Br J Haematol 2001; 113: 5336.
  • 24
    D'Orion R, Pipe SW, Jacquemin M. Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development. Haemophilia 2008; 14(Suppl. 3): 13846.
  • 25
    Rodgers SE, Duncan EM, Sobieraj-Teagure M, Lloyd JV. Evaluation of three automated chromogenic FVIII kits for the diagnosis of mild discrepant haemophilia A. Int J Lab Hematol 2009; 31: 1808.